Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Kariv Tomer	2. Issuer Name and Ticker or Trading Symbol Arno Therapeutics, Inc [ ARNI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) 200 ROUTE 31 NORTH, SUITE 104	3. Date of Earliest Transaction (MM/DD/YYYY) 4/7/2016
(Street) FLEMINGTON, NJ 08822 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 4/11/2016	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								1347327	I	By Pontifax (Cayman) II L.P. ⁽¹⁾
Common Stock								1014888	I	By Pontifax (Israel) II L.P. ⁽¹⁾
Common Stock								393968	I	By Pontifax (Israel) II - Individual Investors L.P. ⁽¹⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$8.00							⁽²⁾	11/5/2020	Common Stock	3750		3750	D
Stock Option (right to buy)	$2.40							⁽³⁾	11/4/2023	Common Stock	68448		68448	D
Stock Option (right to buy)	$2.90							⁽²⁾	1/24/2024	Common Stock	34224		34224	D
Stock Option (right to buy)	$.37	4/7/2016		A		88628		⁽⁴⁾	4/7/2026	Common Stock	88628	$0	88628	D
2012 Series A Warrants (right to buy)	$1.36							12/18/2012	12/18/2017	Common Stock	599064		599064	I	Pontifax (Cayman) II L.P. ⁽¹⁾
2013 Series D Warrants (right to buy)	$2.14							10/29/2013	10/29/2018	Common Stock	380714		380714	I	Pontifax (Cayman) II L.P. ⁽¹⁾
2012 Series A Warrants (right to buy)	$1.36							12/18/2012	12/18/2017	Common Stock	451252		451252	I	Pontifax (Israel) II L.P. ⁽¹⁾
2013 Series D Warrants (right to buy)	$2.14							10/29/2013	10/29/2018	Common Stock	286777		286777	I	Pontifax (Israel) II L.P. ⁽¹⁾
2012 Series A Warrants (right to buy)	$1.36							12/18/2012	12/18/2017	Common Stock	175170		175170	I	Pontifax (Israel) II - Individual Investors L.P. ⁽¹⁾
2013 Series D Warrants (right to buy)	$2.14							10/29/2013	10/29/2018	Common Stock	111323		111323	I	Pontifax (Israel) II - Individual Investors L.P. ⁽¹⁾

Explanation of Responses:
( 1)	The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
( 2)	Currently exercisable.
( 3)	Vests in equal 36-monthly installments commencing 12/4/13.
( 4)	Vests in equal 12-monthly installments commencing 5/7/16.

Remarks:
Due to a technical error, the Form 4 submitted on April 11, 2016 was a duplicate of the Form 4 filing previously (and correctly) submitted on January 14, 2016. This filing contains the accurate information intended to be contained within the April 11, 2016 filing.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Kariv Tomer 200 ROUTE 31 NORTH SUITE 104 FLEMINGTON, NJ 08822	X

Signatures
/s/ Christopher J. Melsha as Attorney-in-Fact for Tomer Kariv pursuant to Power of Attorney previously filed.		4/15/2016
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.